Detailed description page of ThPDB2

This page displays user query in tabular form.

Th1050 details
Primary information
ID10358
Therapeutic IDTh1050
Protein NamePegademase bovine
Sequence>Th1050_Pegademase_bovine MAQTPAFNKPKVELHVHLDGAIKPETILYYGRKRGIALPADTPEELQNIIGMDKPLSLPEFLAKFDYYMPAIAGCREAVKRIAYEFVEMKAKDGVVYVEVRYSPHLLANSKVEPIPWNQAEGDLTPDEVVSLVNQGLQEGERDFGVKVRSILCCMRHQPSWSSEVVELCKKYREQTVVAIDLAGDETIEGSSLFPGHVKAYAEAVKSGVHRTVHAGEVGSANVVKEAVDTLKTERLGHGYHTLEDATLYNRLRQENMHFEVCPWSSYLTGAWKPDTEHPVVRFKNDQVNYSLNTDDPLIFKSTLDTDYQMTKNEMGFTEEEFKRLNINAAKSSFLPEDEKKELLDLLYKAYGMPSPASAEQCL
Molecular Weight40788.2
Chemical FormulaC1821H2834N484O552S14
Isoelectric Point5.33
Hydrophobicity-0.428
Melting pointNA
Half-life72-144 hours
DescriptionBovine adenosine deaminase derived from bovine intestine that has been extensively pegylated for extended serum half life.
Indication/DiseaseFor treatment of adenosine deaminase deficiency
PharmacodynamicsUsed to replace deficient or inactive adenosine deaminase which leads to severe combined immunodeficiency disease (SCID). The enzyme is responsible for converting adenosine to inosine. In the absence of adenosine deaminase, the purine substrates adenosine 2-deoxyadenosine and their metabolites are actually toxic to lymphocytes thereby leading to diminished immune function.
Mechanism of ActionPegademase converts adenosine (toxic) to inosine (less toxic) by deamination. It also converts 2'-deoxyadenosine to 2'-deoxyinosine via deamination.
ToxicityNA
MetabolismNA
AbsorptionNA
NA
ClearanceNA
CategoriesAdjuvants, Immunologic, Aminohydrolases, Antineoplastic and Immunomodulating Agents, Bovine Intestinal Adenosine Deaminase, Enzymes, Enzymes and Coenzymes, Hydrolases, Nucleoside Deaminases, Pegylated agents, Severe Combined Immunodeficiency
Patents NumberNA
Date of IssueNA
Date of ExpiryNA
Drug InteractionKrystexxa (pegloticase)
TargetAdenosine,Growth factor receptor-bound protein 2
Brand NameAdagen
CompanyEnzon Inc.
Brand DescriptionEnzon Inc.
Prescribed ForIt is used for Treating severe combined immunodeficiency disease (SCID) in certain patients with adenosine deaminase (ADA) deficiency.
Chemical Name(monomethoxypolyethylene glycol succinimidyl) 11-17_ adenosine deaminase
FormulationEach ml of ADAGEN injection contains, 250 units of Pegademase bovine, 20 mg of Monobasic sodium phoshphate, USP, 5.58 mg of Dibasic sodium phoshphate, USP, 8.50 mg of Sodiium chloride, USP and q.s. to 0 ml of water for injection.
Physical Appearance Isotonic, pyrogen free, Sterile solution, pH 7.2-7.4
Route of AdministrationIntramusular Injection
Recommended DosageThe dosage of ADAGEN (pegademase bovine) Injection should be individualized. The recommended dosing schedule is 10 U/kg for the first dose, 15 U/kg for the second dose, and 20 U/kg for the third dose. The usual maintenance dose is 20 U/kg per week. Further increases of 5 U/kg/week may be necessary, but a maximum single dose of 30 U/kg should not be exceeded.
ContraindicationAllergic
Side EffectsRash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue; dark urine; severe or persistent tiredness or weakness; unusual bruising or bleeding
Useful Link 1Link
Useful Link 2NA
RemarksNA


Primary information
ID10359
Therapeutic IDTh1050
Protein NamePegademase bovine
Sequence>Th1050_Pegademase_bovine MAQTPAFNKPKVELHVHLDGAIKPETILYYGRKRGIALPADTPEELQNIIGMDKPLSLPEFLAKFDYYMPAIAGCREAVKRIAYEFVEMKAKDGVVYVEVRYSPHLLANSKVEPIPWNQAEGDLTPDEVVSLVNQGLQEGERDFGVKVRSILCCMRHQPSWSSEVVELCKKYREQTVVAIDLAGDETIEGSSLFPGHVKAYAEAVKSGVHRTVHAGEVGSANVVKEAVDTLKTERLGHGYHTLEDATLYNRLRQENMHFEVCPWSSYLTGAWKPDTEHPVVRFKNDQVNYSLNTDDPLIFKSTLDTDYQMTKNEMGFTEEEFKRLNINAAKSSFLPEDEKKELLDLLYKAYGMPSPASAEQCL
Molecular Weight40788.2
Chemical FormulaC1821H2834N484O552S14
Isoelectric Point5.33
Hydrophobicity-0.428
Melting pointNA
Half-life72-144 hours
DescriptionBovine adenosine deaminase derived from bovine intestine that has been extensively pegylated for extended serum half life.
Indication/DiseaseFor treatment of adenosine deaminase deficiency
PharmacodynamicsUsed to replace deficient or inactive adenosine deaminase which leads to severe combined immunodeficiency disease (SCID). The enzyme is responsible for converting adenosine to inosine. In the absence of adenosine deaminase, the purine substrates adenosine 2-deoxyadenosine and their metabolites are actually toxic to lymphocytes thereby leading to diminished immune function.
Mechanism of ActionPegademase converts adenosine (toxic) to inosine (less toxic) by deamination. It also converts 2'-deoxyadenosine to 2'-deoxyinosine via deamination.
ToxicityNA
MetabolismNA
AbsorptionNA
NA
ClearanceNA
CategoriesAdjuvants, Immunologic, Aminohydrolases, Antineoplastic and Immunomodulating Agents, Bovine Intestinal Adenosine Deaminase, Enzymes, Enzymes and Coenzymes, Hydrolases, Nucleoside Deaminases, Pegylated agents, Severe Combined Immunodeficiency
Patents NumberNA
Date of IssueNA
Date of ExpiryNA
Drug InteractionPegloticase
TargetNA
Brand NameNA
CompanyNA
Brand DescriptionNA
Prescribed ForNA
Chemical NameNA
FormulationNA
Physical Appearance NA
Route of AdministrationNA
Recommended DosageNA
ContraindicationNA
Side EffectsHeadache; pain or redness at the injection site.
Useful Link 1Link
Useful Link 2NA
RemarksNA


Primary information
ID10360
Therapeutic IDTh1050
Protein NamePegademase bovine
Sequence>Th1050_Pegademase_bovine MAQTPAFNKPKVELHVHLDGAIKPETILYYGRKRGIALPADTPEELQNIIGMDKPLSLPEFLAKFDYYMPAIAGCREAVKRIAYEFVEMKAKDGVVYVEVRYSPHLLANSKVEPIPWNQAEGDLTPDEVVSLVNQGLQEGERDFGVKVRSILCCMRHQPSWSSEVVELCKKYREQTVVAIDLAGDETIEGSSLFPGHVKAYAEAVKSGVHRTVHAGEVGSANVVKEAVDTLKTERLGHGYHTLEDATLYNRLRQENMHFEVCPWSSYLTGAWKPDTEHPVVRFKNDQVNYSLNTDDPLIFKSTLDTDYQMTKNEMGFTEEEFKRLNINAAKSSFLPEDEKKELLDLLYKAYGMPSPASAEQCL
Molecular Weight40788.2
Chemical FormulaC1821H2834N484O552S14
Isoelectric Point5.33
Hydrophobicity-0.428
Melting pointNA
Half-life72-144 hours
DescriptionBovine adenosine deaminase derived from bovine intestine that has been extensively pegylated for extended serum half life.
Indication/DiseaseFor treatment of adenosine deaminase deficiency
PharmacodynamicsUsed to replace deficient or inactive adenosine deaminase which leads to severe combined immunodeficiency disease (SCID). The enzyme is responsible for converting adenosine to inosine. In the absence of adenosine deaminase, the purine substrates adenosine 2-deoxyadenosine and their metabolites are actually toxic to lymphocytes thereby leading to diminished immune function.
Mechanism of ActionPegademase converts adenosine (toxic) to inosine (less toxic) by deamination. It also converts 2'-deoxyadenosine to 2'-deoxyinosine via deamination.
ToxicityNA
MetabolismNA
AbsorptionNA
NA
ClearanceNA
CategoriesAdjuvants, Immunologic, Aminohydrolases, Antineoplastic and Immunomodulating Agents, Bovine Intestinal Adenosine Deaminase, Enzymes, Enzymes and Coenzymes, Hydrolases, Nucleoside Deaminases, Pegylated agents, Severe Combined Immunodeficiency
Patents NumberNA
Date of IssueNA
Date of ExpiryNA
Drug InteractionNA
TargetNA
Brand NameNA
CompanyNA
Brand DescriptionNA
Prescribed ForNA
Chemical NameNA
FormulationNA
Physical Appearance NA
Route of AdministrationNA
Recommended DosageNA
ContraindicationNA
Side EffectsNA
Useful Link 1Link
Useful Link 2NA
RemarksNA